261 related articles for article (PubMed ID: 25203609)
21. Targeted tumor theranostics using folate-conjugated and camptothecin-loaded acoustic nanodroplets in a mouse xenograft model.
Chen WT; Kang ST; Lin JL; Wang CH; Chen RC; Yeh CK
Biomaterials; 2015; 53():699-708. PubMed ID: 25890765
[TBL] [Abstract][Full Text] [Related]
22. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
Leamon CP; Cooper SR; Hardee GE
Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
[TBL] [Abstract][Full Text] [Related]
25. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners.
Okamoto S; Kawamura K; Li Q; Yamanaka M; Yang S; Fukamachi T; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
J Thorac Oncol; 2012 May; 7(5):873-82. PubMed ID: 22481236
[TBL] [Abstract][Full Text] [Related]
26. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
27. Design of Multifunctional Liposomal Nanocarriers for Folate Receptor-Specific Intracellular Drug Delivery.
Kang MH; Yoo HJ; Kwon YH; Yoon HY; Lee SG; Kim SR; Yeom DW; Kang MJ; Choi YW
Mol Pharm; 2015 Dec; 12(12):4200-13. PubMed ID: 26544061
[TBL] [Abstract][Full Text] [Related]
28. Anti-angiogenic and anti-tumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer.
Cai XJ; Wang Z; Cao JW; Ni JJ; Xu YY; Yao J; Xu H; Liu F; Yang GY
Oncotarget; 2017 Oct; 8(48):84248-84257. PubMed ID: 29137420
[TBL] [Abstract][Full Text] [Related]
29. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
Gabizon A; Shmeeda H; Horowitz AT; Zalipsky S
Adv Drug Deliv Rev; 2004 Apr; 56(8):1177-92. PubMed ID: 15094214
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
[TBL] [Abstract][Full Text] [Related]
31. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo evaluation of (99m)Tc-DO3A-EA-Folate for receptor-mediated targeting of folate positive tumors.
Mishra G; Hazari PP; Kumar N; Mishra AK
J Drug Target; 2011 Nov; 19(9):761-9. PubMed ID: 21425922
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
34. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
[TBL] [Abstract][Full Text] [Related]
35. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
Marra M; Salzano G; Leonetti C; Tassone P; Scarsella M; Zappavigna S; Calimeri T; Franco R; Liguori G; Cigliana G; Ascani R; La Rotonda MI; Abbruzzese A; Tagliaferri P; Caraglia M; De Rosa G
Nanomedicine; 2011 Dec; 7(6):955-64. PubMed ID: 21453789
[TBL] [Abstract][Full Text] [Related]
36. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro.
Lee RJ; Low PS
Biochim Biophys Acta; 1995 Feb; 1233(2):134-44. PubMed ID: 7865538
[TBL] [Abstract][Full Text] [Related]
37. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
Ni S; Stephenson SM; Lee RJ
Anticancer Res; 2002; 22(4):2131-5. PubMed ID: 12174894
[TBL] [Abstract][Full Text] [Related]
38. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
Ross TL; Honer M; Lam PY; Mindt TL; Groehn V; Schibli R; Schubiger PA; Ametamey SM
Bioconjug Chem; 2008 Dec; 19(12):2462-70. PubMed ID: 19053298
[TBL] [Abstract][Full Text] [Related]
39. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Mandelbaum-Shavit F; Qazen MM; Zalipsky S
Bioconjug Chem; 1999; 10(2):289-98. PubMed ID: 10077479
[TBL] [Abstract][Full Text] [Related]
40. Liposome-encapsulated zoledronate increases inflammatory macrophage population in TNBC tumours.
Petruk N; Sousa S; Croset M; Polari L; Zlatev H; Selander K; Mönkkönen J; Clézardin P; Määttä J
Eur J Pharm Sci; 2023 Nov; 190():106571. PubMed ID: 37652236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
